Drug Trial Radar · NCT04628767
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
131
Planned (sponsor's estimate)
Start
Nov 12, 2021
Primary completion
Sep 30, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Nov 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II/III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Durvalumab in combination with chemotherapy before surgery may enhance the shrinking of the tumor compared to chemotherapy alone.
Conditions
- Renal Pelvis and Ureter Urothelial Carcinoma
Interventions
Biopsy ProcedureProcedure
Undergo tissue biopsy
Biospecimen CollectionProcedure
Undergo blood sample collection
CisplatinDrug
Given IV
Computed TomographyProcedure
Undergo CT
Doxorubicin HydrochlorideDrug
Given Iv
DurvalumabBiological
Given IV
Gemcitabine HydrochlorideDrug
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
MethotrexateDrug
Given IV
PegfilgrastimBiological
Given via injection
Therapeutic Conventional SurgeryProcedure
Undergo surgery
Vinblastine SulfateDrug
Given Iv
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survival (EFS) (Cisplatin eligible cohort: Arms A and B)Time frame: From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
- Pathologic complete response (pCR) (Cisplatin ineligible cohort: Arm C)Time frame: At surgery
Locations
259 sites in 1 country. Site status is shown where the registry gives one.
Kingman Regional Medical Center
Kingman, Arizona · Recruiting
Mercy Hospital Fort Smith
Fort Smith, Arkansas · Suspended
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Active not recruiting
Sutter Auburn Faith Hospital
Auburn, California · Active not recruiting
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California · Active not recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Active not recruiting
Palo Alto Medical Foundation-Fremont
Fremont, California · Active not recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
Memorial Medical Center
Modesto, California · Active not recruiting
Palo Alto Medical Foundation-Camino Division
Mountain View, California · Active not recruiting
Palo Alto Medical Foundation Health Care
Palo Alto, California · Active not recruiting
Stanford Cancer Institute Palo Alto
Palo Alto, California · Recruiting
Sutter Roseville Medical Center
Roseville, California · Active not recruiting
Sutter Medical Center Sacramento
Sacramento, California · Active not recruiting
UC San Diego Medical Center - Hillcrest
San Diego, California · Recruiting
California Pacific Medical Center-Pacific Campus
San Francisco, California · Active not recruiting
Palo Alto Medical Foundation-Santa Cruz
Santa Cruz, California · Active not recruiting
Sutter Pacific Medical Foundation
Santa Rosa, California · Active not recruiting
Palo Alto Medical Foundation-Sunnyvale
Sunnyvale, California · Active not recruiting
Sutter Solano Medical Center/Cancer Center
Vallejo, California · Active not recruiting
UCHealth University of Colorado Hospital
Aurora, Colorado · Recruiting
UCHealth - Cherry Creek
Denver, Colorado · Suspended
Poudre Valley Hospital
Fort Collins, Colorado · Recruiting
Cancer Care and Hematology-Fort Collins
Fort Collins, Colorado · Recruiting
UCHealth Greeley Hospital
Greeley, Colorado · Recruiting
UCHealth Highlands Ranch Hospital
Highlands Ranch, Colorado · Recruiting
UCHealth Lone Tree Health Center
Lone Tree, Colorado · Recruiting
Medical Center of the Rockies
Loveland, Colorado · Recruiting
MedStar Washington Hospital Center
Washington D.C., District of Columbia · Recruiting
Sibley Memorial Hospital
Washington D.C., District of Columbia · Recruiting
Mayo Clinic in Florida
Jacksonville, Florida · Active not recruiting
Emory University Hospital Midtown
Atlanta, Georgia · Recruiting
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia · Recruiting
Emory Saint Joseph's Hospital
Atlanta, Georgia · Recruiting
Emory Decatur Hospital
Decatur, Georgia · Recruiting
Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho · Recruiting
OSF Saint Anthony's Health Center
Alton, Illinois · Suspended
Advocate Good Shepherd Hospital
Barrington, Illinois · Recruiting
Illinois CancerCare-Bloomington
Bloomington, Illinois · Active not recruiting
Loyola Center for Health at Burr Ridge
Burr Ridge, Illinois · Active not recruiting
Showing 40 of 259 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.